Expression of osteopontin and cyclooxygenase-2 in colon cancer and its clinical significance

doi:10.3877/cma.j.issn.2095-3224.2019.02.011

Abstract

Abstract:

Objective

To investigate the expression of osteopontin (OPN) and cyclooxygenase-2 (COX-2) in colon cancer tissues and its clinical significance.

Methods

100 cases of colon cancer surgical specimens filed between January 2016 and February 2018 in the Department of Pathology, Fourth People′s Hospital of Hengshui City were selected as the study group, and 100 cases of adjacent normal tissues were selected as the study control group according to 1:1. Immunohistochemistry was used to detect the expression of OPN and COX-2 in the two groups.

Results

The positive rate of OPN expression in the study group was 84.0% higher than that in the control group (17.0%, χ²=89.789, P=0.000). The positive expression rate of COX-2 in the study group was 78.0%, which was significantly higher than that in the control group (32.0%, χ²=42.747, P=0.000). The positive expression of OPN was associated with TNM stage, differentiation and lymph node metastasis of colon cancer (P<0.05). The positive expression of COX-2 was associated with TNM stage and lymph node metastasis of colon cancer (P<0.05). The positive expression of OPN in colon cancer tissues was positively correlated with the positive expression of COX-2 (r=3.821, P=0.000).

Conclusion

It is important to guide the clinical diagnosis and treatment of colon cancer by detecting the expression levels of OPN and COX-2.

Key words: Osteopontin, Colon tumor, Cyclooxygenase-2, Immunohistochemistry

Lingling Zhao, Jingguang Li, Yancai Liu, Chunping Wu, Xuegang Liu, Qinghua Shang. Expression of osteopontin and cyclooxygenase-2 in colon cancer and its clinical significance[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(02): 160-164.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2019.02.011

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2019/V08/I02/160

Figures/Tables 4

References 20

[1]	赵岭岭，吴春平，李景光等. 骨桥蛋白和基质金属蛋白酶-3、10在结肠癌组织中的表达及意义[J].临床和实验医学杂志, 2017, 16(3):240-243.
[2]	李志锋，石荣亚，刘进忠等. 结肠腺癌组织中CDX2、OPN的表达及意义[J].中国现代医学杂志, 2017, 27(20):113-116.
[3]	Norouzi M, Norouzi S, Amini M, et al. Apoptotic Effects of Two COX-2 Inhibitors on Breast Adenocarcinoma Cells Through COX-2 Independent Pathway [J]. Journal of Cellular Biochemistry, 2015, 116(1):81-90.
[4]	赖明广，青海涛，王立生等. microRNA-101和COX-2在结肠癌中的表达及其临床意义[J].实用医学杂志, 2016, 32(5):739-741, 742.
[5]	Lokwani D, Azad R, Sarkate A, et al. Structure Based Library Design (SBLD) for new 1,4-dihydropyrimidine scaffold as simultaneous COX-1/COX-2 and 5-LOX inhibitors [J]. Bioorganic & Medicinal Chemistry, 2015, 23(15):4533-4543.
[6]	沈炜，俞士尤，邵正才, 等. 新辅助化疗与营养支持对老年结肠癌患者T细胞, COX-2及tM2-PK水平的影响[J]. 现代生物医学进展, 2015, 15(36):7135-7138.
[7]	王海英，陈恩乐，周琴, 等. 新辅助化疗对结肠癌细胞凋亡及相关调控蛋白表达的影响[J].中华实验外科杂志, 2015, 32(1):171-174.
[8]	Akasaka H, So SP, Ruan KH. Relationship of the Topological Distances and Activities between mPGES-1 and COX-2 versus COX-1: Implications of the Different Post-Translational Endoplasmic Reticulum Organizations of COX-1 and COX-2 [J]. Biochemistry, 2015, 54(23):3707-3715.
[9]	刘海云，钟睿，谢琛, 等. COX-2表达下调抑制人结肠癌细胞系HT-29增殖并促进凋亡[J]. 基础医学与临床, 2017, 37(11):1568-1573.
[10]	柯晗昵，曲显俊. 乙酰基-11-酮基-β-乳香酸与阿斯匹林对HCT-116作用的比较研究[J]. 中华肿瘤防治杂志, 2015, 22(2):103-108.
[11]	郭东来，李鹏，韩振魁, 等. 塞来昔布抑制人结肠癌细胞COLO205增殖及对COX-2、MMP -9mRNA表达影响的体外实验研究[J].临床和实验医学杂志, 2015, 14(16):1364-1367.
[12]	Ezura Y, Nagata J, Nagao M, et al. Hindlimb-unloading suppresses B cell population in the bone marrow and peripheral circulation associated with OPN expression in circulating blood cells [J]. Journal of Bone and Mineral Metabolism, 2015, 33(1):48-54.
[13]	余卫中，陈兰，刘立红, 等. 核因子-κB、环氧合酶-2在结肠腺瘤性息肉及结肠癌组织的表达及其与血管生成的关系[J].中华实验外科杂志, 2016, 33(12):2776-2779.
[14]	张晓贤，孙剑经，刘华, 等. NS-398对人结肠癌HCT-8细胞增殖、凋亡的影响及机制[J].山东医药, 2016, 56(25):8-12.
[15]	Sarosiek K, Jones E, Chipitsyna G, et al. Osteopontin (OPN) Isoforms, Diabetes, Obesity, and Cancer; What Is One Got to Do with the Other? A New Role for OPN [J]. Journal of Gastrointestinal Surgery, 2015, 19(4):639-650.
[16]	陈吉添，陈瑜，吴薇紫, 等. 结肠癌组织中IGF-IR和COX-2的表达及其临床意义[J]. 临床与实验病理学杂志, 2016, 32(6):620-625.
[17]	Pasandideh M, Mohammadabadi MR.,Esmailizadeh AK, et al. Association of bovine PPARGC1A and OPN genes with milk production and composition in Holstein cattle [J]. Czech Journal of Animal Science, 2015, 60(3):97-104.
[18]	Bouleftour W, Bouet G, Granito RN, et al. Blocking the Expression of Both Bone Sialoprotein (BSP) and Osteopontin (OPN) Impairs the Anabolic Action of PTH in Mouse Calvaria Bone [J]. Journal of Cellular Physiology, 2015, 230(3):568-577.
[19]	韩宏斌，梁宁震，周怡萍, 等.NF-κB、COX-2在结直肠癌组织中的表达及其临床意义[J].临床和实验医学杂志, 2015, 14(16):1342-1344.
[20]	杨佳，王辉，张涛, 等.雌激素通过调节COX-2介导的血管生成减弱DMH的诱癌作用[J].华中科技大学学报(医学版), 2017, 46(6):647-651.

指标		例数	阳性	阳性率（%）	χ²值	P值
性别		?	?	?	0.510	0.475
?	男性	70	60	85.71	?	?
?	女性	30	24	80.0	?	?
年龄（岁）		?	?	?	3.390	0.065
?	>60	36	27	75.0	?	?
?	≤60	64	57	89.06	?	?
肿瘤大小（cm）		?	?	?	0.519	0.471
?	≥5	52	45	86.53	?	?
?	<5	48	39	81.25	?	?
分化情况		?	?	?	6.002	0.014
?	中高分化	40	38	95.0	?	?
?	低分化	60	46	76.67	?	?
?	肿瘤分期	?	?	?	8.702	0.003
?	Ⅰ~Ⅱ期	22	14	63.36	?	?
?	Ⅲ~Ⅳ期	78	70	89.74	?	?
是否淋巴结转移		?	?	?	6.448	0.011
?	是	54	50	92.59	?	?
?	否	46	34	73.91	?	?
浸润程度		?	?	?	0.320	0.571
?	浸润浆膜	69	57	82.60	?	?
?	浸润浆膜及肌层	31	27	87.09	?	?

指标		例数	阳性	阳性率（%）	χ²值	P值
性别		?	?	?	0.510	0.475
?	男性	70	60	85.71	?	?
?	女性	30	24	80.0	?	?
年龄（岁）		?	?	?	3.390	0.065
?	>60	36	27	75.0	?	?
?	≤60	64	57	89.06	?	?
肿瘤大小（cm）		?	?	?	0.519	0.471
?	≥5	52	45	86.53	?	?
?	<5	48	39	81.25	?	?
分化情况		?	?	?	6.002	0.014
?	中高分化	40	38	95.0	?	?
?	低分化	60	46	76.67	?	?
?	肿瘤分期	?	?	?	8.702	0.003
?	Ⅰ~Ⅱ期	22	14	63.36	?	?
?	Ⅲ~Ⅳ期	78	70	89.74	?	?
是否淋巴结转移		?	?	?	6.448	0.011
?	是	54	50	92.59	?	?
?	否	46	34	73.91	?	?
浸润程度		?	?	?	0.320	0.571
?	浸润浆膜	69	57	82.60	?	?
?	浸润浆膜及肌层	31	27	87.09	?	?

指标		例数	阳性	阳性率（%）	χ²值	P值
性别		?	?	?	1.598	0.206
?	男性	70	57	81.42	?	?
?	女性	30	21	70.0	?	?
年龄（岁）		?	?	?	0.295	0.587
?	>60	36	27	75.0	?	?
?	≤60	64	51	79.68	?	?
肿瘤大小（cm）		?	?	?	0.073	0.786
?	≥5	52	40	76.92	?	?
?	<5	48	38	79.16	?	?
分化情况		?	?	?	0.349	0.554
?	中高分化	40	30	75.0	?	?
?	低分化	60	48	80.0	?	?
?	肿瘤分期	?	?	?	9.042	0.002
?	Ⅰ~Ⅱ期	22	12	54.54	?	?
?	Ⅲ~Ⅳ期	78	66	84.61	?	?
是否淋巴结转移		?	?	?	14.567	0.000
?	是	54	50	92.59	?	?
?	否	46	28	60.86	?	?
浸润程度		?	?	?	0.379	0.537
?	浸润浆膜	69	55	79.71	?	?
?	浸润浆膜及肌层	31	23	74.19	?	?

指标		例数	阳性	阳性率（%）	χ²值	P值
性别		?	?	?	1.598	0.206
?	男性	70	57	81.42	?	?
?	女性	30	21	70.0	?	?
年龄（岁）		?	?	?	0.295	0.587
?	>60	36	27	75.0	?	?
?	≤60	64	51	79.68	?	?
肿瘤大小（cm）		?	?	?	0.073	0.786
?	≥5	52	40	76.92	?	?
?	<5	48	38	79.16	?	?
分化情况		?	?	?	0.349	0.554
?	中高分化	40	30	75.0	?	?
?	低分化	60	48	80.0	?	?
?	肿瘤分期	?	?	?	9.042	0.002
?	Ⅰ~Ⅱ期	22	12	54.54	?	?
?	Ⅲ~Ⅳ期	78	66	84.61	?	?
是否淋巴结转移		?	?	?	14.567	0.000
?	是	54	50	92.59	?	?
?	否	46	28	60.86	?	?
浸润程度		?	?	?	0.379	0.537
?	浸润浆膜	69	55	79.71	?	?
?	浸润浆膜及肌层	31	23	74.19	?	?

Please choose a citation manager

Content to export